Glycycoumarin
CAS No. 94805-82-0
Glycycoumarin( —— )
Catalog No. M24999 CAS No. 94805-82-0
Glycycoumarin is an estrogen agonist, it shows moderate inhibitory effects against CYP1A2 and CYP2B6.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 78 | In Stock |
|
| 5MG | 70 | In Stock |
|
| 10MG | 118 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 340 | In Stock |
|
| 100MG | 505 | In Stock |
|
| 200MG | 728 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGlycycoumarin
-
NoteResearch use only, not for human use.
-
Brief DescriptionGlycycoumarin is an estrogen agonist, it shows moderate inhibitory effects against CYP1A2 and CYP2B6.
-
DescriptionGlycycoumarin is an estrogen agonist, it shows moderate inhibitory effects against CYP1A2 and CYP2B6.
-
In VitroGlycycoumarin, (25 μM; 24 h) combining with ABT-737 (12.5 μM) synergistically, induces cell death in multiple types of liver cancer cell HepG2.Glycycoumarin is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity. Cell Viability Assay Cell Line:HepG2, SMMC-7721, and Huh-7 Concentration:10, 20, 25, 30, and 40 μM Incubation Time:24 hours Result:Induced cell death in multiple types of liver cancer cell lines in a dose-dependent manner.
-
In VivoGlycycoumarin (30 μM-0.3 nM; 5 min) has an inhibitory effect on smooth muscle contraction induced by various types of stimulants through the inhibition of PDEs, especially isozyme 3, followed by the accumulation of intracellular cAMP.Glycycoumarin (10 mg/kg; i.p.; once daily for 4 d) enhances tumor growth inhibition in HepG2 xenograft model in mice and shows synergistical effect with ABT-737 (HY-50907). Animal Model:Male ICR mice (aged 6 weeks, weight 25-30 g)Dosage:30 μM-0.3 nM, 5 min Administration:Result:Inhibited the contraction induced by various types of stimulants, such as CCh, KCI, BaCI(2), and A23187 (calcium ionophore III). Enhanced the relaxation induced by forskolin on CCh-evoked contraction and also enhances the relaxation effect of rolipram. Associated with dose-dependent accumulation of cAMP.Animal Model:HepG2 cancer cells xenograft model in male BALB/c athymic nude mice (6-7 weeks old)Dosage:10 mg/kg Administration:Intraperitoneal injection; once daily for 4 days; ABT-737 group was given 100 mg/kg i.p.Result:Inhibited tumor growth and resulted a reduction of the final tumor weight by 17%.
-
Synonyms——
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorAutophagy|JNK|P450
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number94805-82-0
-
Formula Weight368.37
-
Molecular FormulaC21H20O6
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble
-
SMILESO=C1C(C2=CC=C(O)C=C2O)=CC3=C(OC)C(C/C=C(C)\C)=C(O)C=C3O1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase.Oncotarget. 2016 Oct 4;7(40):65732-65743.
molnova catalog
related products
-
Omeprazole
Omeprazole is a proton pump inhibitor.
-
GC7 Sulfate
GC7 Sulfate is a potent inhibitor of deoxyhypusine synthase (DHS). Eukaryotic translation initiation factor 5A2 (eIF5A2) is the only known substrate for DHS, so GC7 inhibits the activation of eIF5A2 by inhibiting DHS activity.
-
sbp-7455
SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.
Cart
sales@molnova.com